Ranibizumab treatment in groups I and II was superior to vPDT based on mean average BCVA change from baseline to month 1 through month 3 ( group I : +10.5 , group II : +10.6 vs. group III : +2.2 Early Treatment Diabetic Retinopathy Study [ ETDRS ] letters ; both P < 0.0001 ) .